Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DF6002 + nivolumab
- Development stage
- Unknown
- Lead developer
- Dragonfly Therapeutics
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
DF6002 + nivolumab is an investigational combination therapy comprising DF6002, an extended half-life interleukin-12 (IL-12) cytokine IgG Fc fusion protein, together with nivolumab, a programmed death-1 (PD-1) immune checkpoint inhibitor monoclonal antibody. DF6002 is designed to stimulate anti-tumor immune responses by promoting an inflammatory tumor microenvironment via IL-12 signaling; when paired with nivolumab, which blocks PD-1-mediated immune evasion, the combination seeks to enhance anti-tumor immune activity in patients with advanced solid tumors. DF6002 is currently in Phase 1/2 clinical trials as monotherapy and in combination with nivolumab for indications such as melanoma, non-small cell lung cancer, and other solid tumors[1][2][3][4][5][6].
- Brand names
- Opdivo (for nivolumab)
- Other names
- DF6002 + Opdivo
02
Targets
IL-12R (Interleukin-12 receptor)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on DF6002 + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DF6002 + nivolumab.